These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9398054)

  • 41. Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts.
    Kolinsky K; Zhang YE; Dugan U; Heimbrook D; Packman K; Higgins B
    Anticancer Res; 2009 Jan; 29(1):91-8. PubMed ID: 19331137
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer.
    Richter SN; Nadai M; Palumbo M; Palù G
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):199-200. PubMed ID: 19288104
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice.
    Kim R; Hirabayashi N; Nishiyama M; Jinushi K; Toge T; Okada K
    Int J Cancer; 1992 Mar; 50(5):760-6. PubMed ID: 1312063
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial.
    Barone C; Landriscina M; Quirino M; Basso M; Pozzo C; Schinzari G; Di Leonardo G; D'Argento E; Trigila N; Cassano A
    Br J Cancer; 2007 Jan; 96(1):21-8. PubMed ID: 17164761
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
    Cerea G; Vaghi M; Ardizzoia A; Villa S; Bucovec R; Mengo S; Gardani G; Tancini G; Lissoni P
    Anticancer Res; 2003; 23(2C):1951-4. PubMed ID: 12820485
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
    Glynne-Jones R; Falk S; Maughan TS; Meadows HM; Sebag-Montefiore D
    Br J Cancer; 2007 Feb; 96(4):551-8. PubMed ID: 17262086
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sequence-dependent effect of a cyclooxygenase-2 inhibitor on topoisomerase I inhibitor and 5-fluorouracil-induced cytotoxicity of colon cancer cells.
    Chen WS; Liu JH; Liu JM; Lin JK
    Anticancer Drugs; 2004 Mar; 15(3):287-94. PubMed ID: 15014363
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
    Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in a colon cancer cell line.
    Inoue Y; Miki C; Watanabe H; Hiro J; Toiyama Y; Ojima E; Yanagi H; Kusunoki M
    J Gastroenterol; 2006 Dec; 41(12):1149-57. PubMed ID: 17287894
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance.
    Xu JM; Azzariti A; Tommasi S; Lacalamita R; Colucci G; Johnston PG; Church SW; Paradiso A
    Clin Colorectal Cancer; 2002 Nov; 2(3):182-8. PubMed ID: 12482336
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
    Javle MM; Cao S; Durrani FA; Pendyala L; Lawrence DD; Smith PF; Creaven PJ; Noel DC; Iyer RV; Rustum YM
    Clin Cancer Res; 2007 Feb; 13(3):965-71. PubMed ID: 17289892
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides.
    Agrawal S; Kandimalla ER; Yu D; Hollister BA; Chen SF; Dexter DL; Alford TL; Hill B; Bailey KS; Bono CP; Knoerzer DL; Morton PA
    Int J Oncol; 2001 May; 18(5):1061-9. PubMed ID: 11295057
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines.
    Kano Y; Akutsu M; Tsunoda S; Mori K; Suzuki K; Adachi KI
    Cancer Chemother Pharmacol; 1998; 42(2):91-8. PubMed ID: 9654107
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma.
    Guo B; Cao S; Tóth K; Azrak RG; Rustum YM
    Clin Cancer Res; 2000 Feb; 6(2):718-24. PubMed ID: 10690558
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Irinotecan: various administration schedules, study of drug combinations, phase I experience].
    Boige V; Raymond E; Armand JP
    Bull Cancer; 1998 Dec; Spec No():26-32. PubMed ID: 9932081
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro antitumor activity of 9-nitro-camptothecin as a single agent and in combination with other antitumor drugs.
    Bernacki RJ; Pera P; Gambacorta P; Brun Y; Greco WR
    Ann N Y Acad Sci; 2000; 922():293-7. PubMed ID: 11193904
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro schedule-dependent interaction between irinotecan and vinorelbine in NCI H460 non-small cell lung cancer cell line.
    Gauvin A; Bressolle F; Martineau P; Astre C; Pinguet F
    Anticancer Res; 2002; 22(2A):905-12. PubMed ID: 12014670
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells.
    Bertrand R; O'Connor PM; Kerrigan D; Pommier Y
    Eur J Cancer; 1992; 28A(4-5):743-8. PubMed ID: 1326304
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.
    Kaufmann SH; Peereboom D; Buckwalter CA; Svingen PA; Grochow LB; Donehower RC; Rowinsky EK
    J Natl Cancer Inst; 1996 Jun; 88(11):734-41. PubMed ID: 8637027
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The therapeutic impact of dipyridamole: chemopotentiation of the cytotoxic combination 5-fluorouracil/cisplatin in an animal model of human bladder cancer.
    Keane TE; Rosner GL; Gingrich JR; Poulton SH; Walther PJ
    J Urol; 1991 Nov; 146(5):1418-24. PubMed ID: 1942313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.